Business Context and Reporting Period
Company: Apollomics Inc. (Nasdaq: APLM)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Apollomics is a clinical-stage biotechnology company focused on discovering and developing oncology therapies. The company has no products approved for commercial sale and generates no product revenue. Its primary asset is its pipeline, led by vebreltinib (APL-101), a c-Met inhibitor. The company operates as a Cayman Islands exempted company with subsidiaries in the U.S., China, Australia, and Hong Kong.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(53.9) million | $(172.6) million |
| Net Loss from Operations | $(53.6) million | $(50.7) million |
| Research & Development Expenses | $(24.6) million | $(34.2) million |
| Administrative Expenses | $(17.8) million | $(20.6) million |
| Impairment of Intangible Assets | $(13.0) million | $0 |
| Cash and Cash Equivalents (Ending) | $9.8 million | $32.1 million |
| Net Cash Used in Operating Activities | $(28.7) million | $(43.2) million |
| Accumulated Deficit | $(700.8) million | $(647.0) million |
Material Changes vs. Prior Period
- Net Loss Reduction: The net loss decreased significantly from $172.6 million in 2023 to $53.9 million in 2024. This improvement is primarily due to the absence of the $76.4 million non-cash fair value change of convertible preferred shares recorded in 2023 (all preferred shares were converted to common stock in March 2023).
- Expense Reductions: The company implemented significant expense reductions in January and July 2024, including a narrowed development focus for vebreltinib, pipeline cuts, and reductions in executive and non-executive employees. R&D expenses decreased by 28.2% year-over-year.
- Intangible Asset Impairment: The company recorded a $13.0 million impairment loss in 2024. This included a $10.0 million write-down of the uproleselan program following negative Phase 3 results from its licensor, GlycoMimetics, and a $3.0 million impairment related to patent rights where the vendor failed to provide drug supplies.
- Liquidity Decline: Cash and cash equivalents decreased by approximately $22.3 million, from $32.1 million to $9.8 million, reflecting continued operating cash outflows.
Guidance, Outlook, and Risks
Liquidity and Going Concern: Based on its 2025 operating plan, the expected receipt of a $10.0 million upfront payment from a new collaboration with LaunXP International (announced March 31, 2025), and its cash balance of $9.8 million, management estimates it has sufficient liquidity to continue as a going concern through at least December 31, 2025. However, the company will require additional capital from equity, debt, or strategic partnerships to continue operations beyond that date.
Strategic Outlook: The company is prioritizing the development of vebreltinib for Non-Small Cell Lung Cancer (NSCLC) with c-Met amplification and Met Exon 14 skipping. It has terminated the uproleselan program and the APL-810 license. The company plans to seek development and commercialization partnerships to optimize efficiency.
Key Risks and Contingencies:
- Capital Requirements: There is no assurance that additional capital will be available on acceptable terms. Failure to raise capital could force the company to delay or eliminate development programs.
- Clinical Trial Risks: The company is heavily dependent on the success of vebreltinib. Clinical trials may fail to demonstrate safety or efficacy, or regulatory approval may be delayed or denied.
- Intellectual Property: The company faces potential third-party patent challenges (e.g., "Structure Patents" expiring in 2026) that could delay commercialization or require licensing fees.
- Internal Controls: While a material weakness identified in 2023 was remediated in 2024, one significant deficiency regarding segregation of duties in financial reporting software remained as of December 31, 2024.
- Legal Proceedings: The company is defending a claim by two minority investors seeking up to $40 million in connection with alleged redemption requests prior to the 2023 business combination.
Investor Verification Checklist
- Cash Runway: Verify the timing and certainty of the $10.0 million upfront payment from LaunXP International to confirm the "going concern" assessment through 2025.
- Veberltinib Enrollment: Monitor enrollment rates for the SPARTA trial, specifically the cohort for NSCLC with c-Met amplification, which requires non-standard genetic testing and has historically faced slow enrollment.
- Patent Litigation: Assess the status of negotiations or litigation regarding third-party "Structure Patents" that could impact the commercial launch of vebreltinib before December 2026.
- Internal Controls: Review the remediation plan for the remaining significant deficiency in financial reporting software segregation of duties.
- Legal Defense: Track the progress of the Cayman Islands litigation regarding the $40 million claim from minority investors.